Renaissance Technologies LLC Sells 84,301 Shares of Amedisys, Inc. (NASDAQ:AMED)

Renaissance Technologies LLC decreased its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 70.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,800 shares of the health services provider's stock after selling 84,301 shares during the quarter. Renaissance Technologies LLC owned approximately 0.11% of Amedisys worth $3,250,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in AMED. Vanguard Group Inc. lifted its stake in Amedisys by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock valued at $291,992,000 after acquiring an additional 10,817 shares during the last quarter. Norges Bank acquired a new position in Amedisys during the fourth quarter worth approximately $83,061,000. Alpine Associates Management Inc. raised its stake in Amedisys by 3.2% in the fourth quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider's stock valued at $80,632,000 after buying an additional 27,403 shares during the period. Wealthfront Advisers LLC bought a new stake in shares of Amedisys in the 4th quarter valued at about $72,970,000. Finally, Alliancebernstein L.P. raised its position in shares of Amedisys by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 677,787 shares of the health services provider's stock worth $61,536,000 after acquiring an additional 13,587 shares during the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Stock Up 0.2 %

AMED stock traded up $0.23 during mid-day trading on Friday, reaching $94.50. 361,426 shares of the company traded hands, compared to its average volume of 406,625. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of 37.50, a P/E/G ratio of 1.78 and a beta of 0.89. The firm's 50 day moving average price is $92.21 and its 200 day moving average price is $91.79. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. As a group, equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on AMED shares. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Stephens restated an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.